实用肿瘤学杂志 ›› 2010, Vol. 24 ›› Issue (1): 20-23.doi: 10.3969/j.issn.1002-3070.2010.01.005

• 论著 • 上一篇    下一篇

应用蛋白芯片技术筛选肺腺癌化疗敏感血清蛋白标志物

赵健1, 徐维1, 王远东1, 郭爱林2, 薛兴阳1, 李洪胜1, 韩国栋1, 傅文凡1   

  1. 1.广州医学院附属肿瘤医院肺肿瘤外科(广州 510095);
    2.广东省人民医院中心实验室
  • 收稿日期:2009-11-03 出版日期:2010-02-28 发布日期:2015-01-23
  • 作者简介:赵健,男,(1963-),博士,主任医师,从事肺癌的基础与临床研究
  • 基金资助:
    广东省自然科学基金(编号:5300412),广州市教育局科技社科基金资助(编号:61037)

Screening on the serum protein markers for predicting lung adenocarcinoma chemotherapy sensitivity with the SELDI-TOF-MS technique

ZHAO Jian1, XU Wei1, WANG Yuandong1, GUO Ailin2, XUE Xingyang1, LI Hongsheng1, HAN Guodong1, FU Wenfan1   

  1. 1.Department of Pulmonary Tumour surgery,Affiliated Tumour Hospital of Guangzhou Medical University,Guangzhou 510095;
    2.Department of Experiment Center,People′s Hospital of Guangdong Province,Guangzhou 510010
  • Received:2009-11-03 Online:2010-02-28 Published:2015-01-23

摘要: 目的 探讨肺腺癌化疗敏感患者与化疗耐药患者血清蛋白质质谱的不同,筛选肺腺癌化疗敏感血清蛋白标志物。方法 用WCX2蛋白芯片结合表面增强激光解析电离飞行时间质谱(SELDI-TOF-MS)技术,检测22例肺腺癌化疗敏感的患者和21例化疗不敏感的血清蛋白质谱,筛选出差异表达蛋白质。结果 发现利用M/Z(质荷比)为16083.50Da,7963.17Da,16121.50Da,15921.60Da,8066.79Da,8040.17Da和3394.57Da的7个差异蛋白可区分标准含铂类方案化疗敏感组和耐药组,联合m/z为7963.17Da与16083.50Da的差异蛋白建立预测模型,可预测肺腺癌标准含铂类方案化疗敏感/耐药性,其敏感性86.36%和特异性80.95%。结论 SELDI-TOF-MS技术是寻找肺腺癌化疗敏感血清诊断标志物的有效工具。

Abstract: Objective To explore the difference of serum protein mass spectrometry between the sensitive and drug resistance lung adenocarcinoma patients,and to discover serum protein markers for predicting chemotherapy sensitivity of lung adenocarcinoma patients.Methods To detect the protein mass spectrometry of 22 chemosensitive lung adenocarcinoma patients and 21 chemotherapy-resistant cases with WCX2 protein chip combining with SELDI-TOF-MS technique,and then screen differentially expressed proteins.Results In this experiment,7 differentially expressed proteins were screened,which can differentiate the chemosensitive or the chemotherapy-resistant patients with standard platinum-based chemotherapy.The m/z value of them is 16083.50Da,7963.17Da,16121.50Da,15921.60Da,8066.79Da,8040.17Da and 3394.57Da respectively.Predictive model with M/Z 7963.17Da and 16083.50Da could differentiate the chemosensitive or the chemotherapy-resistant patients,whose sensitivity was 86.36% and specificity was 80.95%.Conclusions SELDI-TOF-MS is an effective instrument to find sensitive serum marker for predicting lung adenocarcinoma chemotherapy sensitivity.

中图分类号: